Targeting LSD1 for acute myeloid leukemia (AML) treatment

被引：57
|
作者：
Zhang, Shujing [1 ]
Liu, Menghan [1 ]
Yao, Yongfang [1 ,2 ]
Yu, Bin [1 ,2 ]
Liu, Hongmin [1 ,2 ]
机构：
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Key Lab Adv Drug Preparat Technol, Minist Educ, Zhengzhou 450001, Peoples R China
[2] Zhengzhou Univ, Sch Pharmaceut Sci, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450052, Henan, Peoples R China
来源：
PHARMACOLOGICAL RESEARCH | 2021年 / 164卷
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
Histone demethylase; AML treatment; LSD1; inhibitors; Tranylcypromine derivatives; Combination therapy; TRANS-RETINOIC ACID; DEMETHYLASE; LSD1; ARSENIC TRIOXIDE; REVERSIBLE INHIBITORS; HISTONE METHYLATION; POTENT INHIBITORS; ATRA-RESISTANCE; DIFFERENTIATION; THERAPY; TRANYLCYPROMINE;
D O I：
10.1016/j.phrs.2020.105335
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently there are very limited therapeutic targets for AML treatment. Histone lysine specific demethylase 1 (LSD1) is highly expressed in many cancers, impedes the differentiation of cancer cells, promotes the proliferation, metastasis and invasion of cancer cells, and is associated with poor prognosis. Targeting LSD1 has been recognized as a promising strategy for AML treatment in recent years. Based on these features, in the review, we discussed the main epigenetic drugs targeting LSD1 for AML therapy. Thus, this review focuses on the progress of LSD1 inhibitors in AML treatment, particularly those such as tranylcypromine (TCP), ORY-1001, GSK2879552, and IMG-7289 in clinical trials. These inhibitors provide novel scaffolds for designing new LSD1 inhibitors. Besides, combined therapies of LSD1 inhibitors with other drugs for AML treatment are also highlighted.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Targeting the LSD1/ADNP axis as an effective pro-differentiating strategy against acute myeloid leukemia AML
    Lone, Mehraju Din
    Sayeed, Mohd
    Habieb, Alaa
    Kumar, Praveen
    Engel, Michael E.
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia
    Kruger, Ryan G.
    Mohammad, Helai
    Smitheman, Kimberly
    Cusan, Monica
    Liu, Yan
    Pappalardi, Melissa
    Federowicz, Kelly
    Van Aller, Glenn
    Kasparec, Jiri
    Tian, Xinrong
    Suarez, Dominic
    Rouse, Meagan
    Schneck, Jessica
    Carson, Jeffrey
    McDevitt, Patrick
    Ho, Thau
    McHugh, Charles
    Miller, William
    Johnson, Neil
    Armstrong, Scott A.
    Tummino, Peter
    BLOOD, 2013, 122 (21) : 3964 - 3867
  • [3] LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism
    Singh, Kanwaldeep
    Hartung, Emily
    Muhs, Christina
    Alshamleh, Islam
    Divakaran, Monisha
    Dvorkin-Gheva, Anna
    Pishyar, Sara
    Prabagaran, Pradhariny
    Khalaf, Dina
    Garcia-Horton, Alejandro
    Foley, Stephen Ronan
    Leber, Brian
    Walker, Irwin
    Lepic, Kylie
    Schwalbe, Harald
    Serve, Hubert
    Kleppe, Maria
    Young, Rienhoff Hugh, Jr.
    Berg, Tobias
    BLOOD, 2023, 142
  • [4] Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia
    Przespolewski, Amanda
    Wang, Eunice S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (07) : 771 - 780
  • [5] Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
    Yashar, William M.
    Curtiss, Brittany M.
    Coleman, Daniel J.
    VanCampen, Jake
    Kong, Garth
    Macaraeg, Jommel
    Estabrook, Joseph
    Demir, Emek
    Long, Nicola
    Bottomly, Daniel
    McWeeney, Shannon K.
    Tyner, Jeffrey W.
    Druker, Brian J.
    Maxson, Julia E.
    Braun, Theodore P.
    MOLECULAR CANCER RESEARCH, 2023, 21 (07) : 631 - 647
  • [6] Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML
    Luciano Nicosia
    Francesca Ludovica Boffo
    Elena Ceccacci
    Fabio Conforti
    Isabella Pallavicini
    Fabio Bedin
    Roberto Ravasio
    Enrico Massignani
    Tim C. P. Somervaille
    Saverio Minucci
    Tiziana Bonaldi
    Oncogene, 2022, 41 : 878 - 894
  • [7] Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML
    Nicosia, Luciano
    Boffo, Francesca Ludovica
    Ceccacci, Elena
    Conforti, Fabio
    Pallavicini, Isabella
    Bedin, Fabio
    Ravasio, Roberto
    Massignani, Enrico
    Somervaille, Tim C. P.
    Minucci, Saverio
    Bonaldi, Tiziana
    ONCOGENE, 2022, 41 (06) : 878 - 894
  • [8] Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia
    Teresa Borrello, Maria
    Benelkebir, Hanae
    Lee, Adam
    Hin Tam, Chak
    Shafat, Manar
    Rushworth, Stuart A.
    Bowles, Kristian M.
    Douglas, Leon
    Duriez, Patrick J.
    Bailey, Sarah
    Crabb, Simon J.
    Packham, Graham
    Ganesan, A.
    CHEMMEDCHEM, 2021, 16 (08) : 1316 - 1324
  • [9] Discovery of novel tranylcypromine-indazole-based derivatives as LSD1 inhibitors for acute myeloid leukemia treatment
    Huang, Ming-Jie
    Liu, Qiuge
    Song, Jian
    Gao, Beiling
    Zhang, Saiyang
    Huang, Lihua
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 289
  • [10] Dual targeting of FLT3 and LSD1 disrupts the MYC super-enhancer complex in acute myeloid leukemia
    Yashar, William M.
    Smith, Brittany M.
    VanCampen, Jake
    Kong, Garth L.
    Macaraeg, Jommel
    Coleman, Daniel J.
    Druker, Brian J.
    Maxson, Julia E.
    Braun, Theodore P.
    CANCER RESEARCH, 2022, 82 (12)
12345